Rubraca
Generic: rucaparib
- Manufacturer
- Pharmaand
- NDC
- 82154-0783
- RxCUI
- 1862584
- Route
- ORAL
- ICD-10 indication
- C56.9
Affordability Check
How much will you actually pay for Rubraca?
In 30 seconds, see every legitimate way to afford Rubraca — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.
About Rubraca
What is this medication? Rubraca, which is known by its generic name rucaparib, is a prescription medication classified as a poly ADP-ribose polymerase inhibitor, or PARP inhibitor. It is primarily used for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumors have responded to previous platinum-based chemotherapy. The medication works by blocking an enzyme that helps repair damaged DNA within cells; by inhibiting this process in cancer cells, Rubraca can cause the cells to die and help slow the progression of the disease.
In addition to its use in gynecological cancers, Rubraca is indicated for the treatment of certain adult patients with a specific type of advanced prostate cancer known as metastatic castration-resistant prostate cancer. Specifically, it is used for patients who have a confirmed deleterious BRCA mutation and who have already undergone treatment with androgen receptor-directed therapy and taxane-based chemotherapy. Because this is a targeted therapy, healthcare providers typically perform genetic testing to confirm the presence of these mutations before starting the treatment.
Copay & patient assistance
- Patient Copay Amount: As little as $0
- Maximum Annual Benefit Limit: Not Publicly Available
- Core Eligibility Restrictions: Must have commercial/private insurance; not eligible if enrolled in government-funded programs (Medicare, Medicaid, TRICARE, VA, DoD, etc.); must reside in the US or US Territories; must be 18 years of age or older; not eligible if the insurance plan implements accumulator adjustment or co-pay maximizer programs.
- RxBIN, PCN, and Group numbers: Not Publicly Available
External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.
Compare pricing elsewhere
RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.
Cost Plus Drug Company
Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for rucaparib.
Browse Cost Plus medications →
GoodRx
Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.
Lookup Rubraca →
NeedyMeds
Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.
Search for rucaparib →
RxAssist
PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.
Search PAPs →
We deep-link because transparency helps patients. None of these partners pay RxCopays.
Conditions we've indexed resources for
Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.
Medicare Part D coverage
How Rubraca appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).
Covered by plans
52%
2,884 of 5,499 plans
Most common tier
Tier 5
On 79% of covering formularies
Prior authorization required
99%
of covering formularies
| Tier | Formularies on this tier | Share |
|---|---|---|
| Tier 1 (preferred generic) | 59 | 18% |
| Tier 2 (generic) | 2 | 1% |
| Tier 4 (non-preferred brand) | 7 | 2% |
| Tier 5 (specialty) | 259 | 79% |
| Tier 6 | 1 | 0% |
Step therapy: 0% of formularies
Quantity limits: 96% of formularies
Coverage breadth: 328 of 65 formularies
How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).
Prior authorization & coverage
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
— Medicare Part D | — | — | — |
Related drugs
EVEROLIMUS
Treats same condition · Everolimus
AVMAPKI FAKZYNJA CO-PACK
Treats same condition · avutometinib potassium and defactinib hydrochloride
Fludeoxyglucose F18
Treats same condition · Fludeoxyglucose F18
Portrazza
Treats same condition · necitumumab
Pilocarpine Hydrochloride
Treats same condition · Pilocarpine Hydrochloride
TEPADINA
Treats same condition · THIOTEPA
AVGEMSI
Treats same condition · Gemcitabine
CLENPIQ
Treats same condition · SODIUM PICOSULFATE, MAGNESIUM OXIDE, and ANHYDROUS CITRIC ACID
Niva Thyroid
Treats same condition · thyroid, porcine
Kisunla
Treats same condition · donanemab-azbt
How this page is sourced
- Drug identity verified against openFDA NDC Directory.
- Label text (when shown) originates from NLM DailyMed.
- Copay and assistance URLs verified periodically; if you hit a broken link, tell us.